Our Focus

Ultimate Medicine develops novel small molecules that improve cognitive function and treat dementia by targeting a unique gut-derived metabolite.

Our Impetus

The causative factors for chronic age-related disease are complex as genetics and environmental factors both count in the pathophysiology of the disease. In addition, the gut barrier plays an important role in disease progression as it grants bioactive metabolites like nutrients, water and hormones access to the body, and prevents the entry of harmful metabolites and toxins.  The integrity of the gut barrier changes as people age, as well as the metabolites supplied, and thus the composition of bioactive metabolites in the serum changes.

Metabolite composition changes highlight the need to identify bioactive serum metabolites that contribute to chronic age-related disease to develop patient tailored metabolite modulating treatments and diagnostic biomarkers. Over the increasing human life span, metabolites can contribute to chronic age-related cognitive impairment.

About Us

Ultimate Medicine AG is a Swiss preclinical pharmaceutical company developing a novel oral treatment for age-related cognitive disorders such as Alzheimer’s disease. Our approach targets a key disease pathway overlooked by current therapies. Backed by decades of pharmaceutical development and commercialization experience, our team focuses on a complementary mechanism to amyloid-β and tau that may slow or halt cognitive decline. A companion diagnostic program enables precise patient selection for trials and treatment. Supported by research published in Nature, our work addresses a major gap in dementia care, aiming to deliver scalable, personalized therapies to the growing global population affected.